Fundraising Fox
Merus
Utrecht, NL · 209 employees on LinkedIn · 4 known investors
Find your way into Merus
Sign up to see every warm intro you have to Merus
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Merus team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Merus develops multispecific antibodies (Biclonics and Triclonics) that bind multiple cancer antigens to treat oncology indications. The company's lead candidate, petosemtamab, is in clinical development for head and neck cancer and colorectal cancer.
Founders & leadership
HL
Hui LiuExecutive Vice President, Chief Business Officer & Head of Merus U.S.2015–2024Hui Liu is an Executive Officer at Merus, a biopharmaceutical company developing multispecific antibodies for cancer treatment.
JC
John CrowleyExecutive Vice President, Chief Financial Officer2016–2019He has served as a CFO at public life sciences companies and as a biotech board director, with experience in corporate strategy, capital raising, M&A transactions, and clinical-stage company operations.
LA
L. Andres SirulnikExecutive Vice President and Chief Medical Officer2016–2020L. Andres Sirulnik trained as an academic researcher and practiced as a hematologist-oncologist for over a decade before joining Regeneron, where he led the hematology clinical development program. He is Executive Officer at Merus, which develops multispecific antibodies for oncology indications.
Board
LM
Lionel M.S. CarnotBoard director
AM
Anand MehraBoard director
JP
GD
Gregory D. PerryBoard director
MT
WB
Wolfgang BertholdBoard director
Investors · 4
Reported raises · per SEC filings
Form D private placements$150.8M disclosed across 3 rounds · 2017–2018
▶$15MraisedJan 2019 · 1 investors · BiotechnologyRule 506(b)
▶$15MraisedJan 2019 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ton LogtenbergExecutive Officer, Director
- Gregory D. PerryDirector
- Lex BakkerExecutive Officer
- Anand MehraDirector
- Mark ThrosbyExecutive Officer
- Russell GreigDirector
- Mark T. IwickiDirector
- John De KruifExecutive Officer
- John P. de KoningDirector
- Len KanavyDirector
- Hui LiuExecutive Officer
- L. Andres SirulnikExecutive Officer
- Peter SilvermanExecutive Officer
- Offering amount
- $15M
- Amount sold
- $15M
- First sale
- Dec 2018
- Incorporated
- Other, Netherlands
- Federal exemptions
- 06b
▶$55.8MraisedFeb 2018 · 9 investors · BiotechnologyRule 506(b)
▶$55.8MraisedFeb 2018 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark ThrosbyExecutive Officer
- Gregory D. PerryDirector
- Mark T. IwickiDirector
- Lionel M.S. CarnotDirector
- Hui LiuExecutive Officer
- Wolfgang BertholdDirector
- Anand MehraDirector
- John CrowleyExecutive Officer
- John P. de KoningDirector
- L. Andres SirulnikExecutive Officer
- Ton LogtenbergExecutive Officer, Director
- Lex BakkerExecutive Officer
- Offering amount
- $55.8M
- Amount sold
- $55.8M
- First sale
- Feb 2018
- Incorporated
- Other, Netherlands
- Federal exemptions
- 06b
▶$80MraisedJan 2017 · 1 investors · BiotechnologyRule 506(b)
▶$80MraisedJan 2017 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Anand MehraDirector
- Wolfgang BertholdDirector
- Shelley MargetsonExecutive Officer
- Mark T. IwickiDirector
- Gregory D. PerryDirector
- Jack B. NielsenDirector
- Lionel M.S. CarnotDirector
- Ton LogtenbergExecutive Officer
- John P. de KoningDirector
- Offering amount
- $80M
- Amount sold
- $80M
- First sale
- Jan 2017
- Incorporated
- Other, Netherlands
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
GlobaldataGlobalData provides an AI-powered intelligence platform that delivers research, market analysis, and predictive insights to enterprises across industries. The platform combines proprietary data, in-house subject matter experts, and AI tools to support critical business decisions.
AgenusAgenus is a biotechnology company developing cancer immunotherapies, including its lead investigational combination of botensilimab (an anti-CTLA-4 antibody) and balstilimab (a PD-1 inhibitor), known as BOT+BAL. It provides access to these investigational medicines for cancer patients through pathways such as clinical trials, Named Patient Programs, and compassionate-use programs across multiple countries.
Companies working in the same space as Merus.
Frequently asked questions
- What does Merus do?
- Merus develops multispecific antibodies (Biclonics and Triclonics) that bind multiple cancer antigens to treat oncology indications. The company's lead candidate, petosemtamab, is in clinical development for head and neck cancer and colorectal cancer.
- Who founded Merus?
- Merus was founded by Ton Logtenberg.
- Who are Merus's investors?
- Merus's investors include Avoro Capital Advisors, Pfizer Venture Investments, RA Capital, Sofinnova Ventures.
- How much funding has Merus raised?
- Merus has disclosed $150.8M raised across 3 rounds.
- Where is Merus headquartered?
- Merus is headquartered in Utrecht, NL.